ライフサイエンスコーパス: mammoplasty

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ity of normal tissue obtained from reduction mammoplasty.

2 east epithelial cells (HBECs) from reduction mammoplasty.

3 normal (nonlactating) samples from reductive mammoplasties.

4 sion in a series of specimens from reduction mammoplasty, adenosis, ductal carcinoma in situ, and inf

5 normal breast tissue samples from reduction mammoplasties and in two independent tissue microarrays

6 d GnRH analogs and surgical therapy includes mammoplasty and phalloplasty.

7 significant association between augmentation mammoplasty and SSc, and are consistent with those repor

8 ng breast fibroblasts derived from reduction mammoplasty and tumor tissues, and human umbilical endot

9 s within tumors and in tissue from reduction mammoplasties, and by epithelial-derived tumor cells.

10 parately purified from a set of 10 reduction mammoplasties by using a double antibody magnetic affini

11 combining partial mastectomy with reduction mammoplasty could provide a safe oncologic procedure wit

12 Whereas inclusion of normal reduction mammoplasty fibroblasts inhibit or retard morphological

13 Samples from bilateral reduction mammoplasty from 10 women without any clinical, radiolog

14 , established from tissue taken at reduction mammoplasty from three individuals.

15 s were also selected as a control (reduction mammoplasty group).

16 She underwent bilateral reduction mammoplasty in June 1995 to treat progressive breast enl

17 re providing data on history of augmentation mammoplasty, including possible complications of the pro

18 ary epithelial cells enriched from reduction mammoplasties (n = 9).

19 rom breast cancer patients or from reduction mammoplasty operations expressed comparable estradiol 2-

20 reast epithelial cells from either reduction mammoplasty or nonmalignant breast cell lines, we observ

21 partial mastectomy and concurrent reduction mammoplasty performed at our institution from 2000 to 20

22 837 cases reported a history of augmentation mammoplasty prior to diagnosis of SSc, compared with 31

23 ve simultaneous partial mastectomy/reduction mammoplasty procedures were performed in 79 patients.

24 r who have previously undergone augmentation mammoplasty result in a high prevalence of capsular cont

25 m 29 noncancer patients undergoing reduction mammoplasty served as controls.

26 sues and from epithelial cells purified from mammoplasty specimens.

27 and evaluation of the skin during reduction mammoplasty surgery in two patients.

28 partial mastectomy with concurrent reduction mammoplasty technique is a viable option for breast cons

29 degrees of risk (those undergoing reduction mammoplasties, those with atypical hyperplastic prolifer

30 thelial cells (HMEC) isolated from reduction mammoplasty tissue are proliferative for several passage

31 helial cells (HMECs) isolated from reduction mammoplasty tissue of seven individual donors.

32 (HMEC) culture model, derived from reduction mammoplasty tissue, and found that ectopic expression of

33 ionally normal breast tissues from reduction mammoplasty tissues, in what we term the human-in-mouse

34 e from healthy patients undergoing reduction mammoplasty was also studied.

35 from 40 women undergoing elective reduction mammoplasty were extracted by a solid-phase procedure.

36 (95% CI) for the association of augmentation mammoplasty with SSc were estimated by multivariate logi

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。